{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:28:17Z","timestamp":1794511697466,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/CS0019\/CS\/01\/20 Dt.12.04.2021"],"award-info":[{"award-number":["BT\/CS0019\/CS\/01\/20 Dt.12.04.2021"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology, Govt. of India."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike intramuscular vaccines, intranasal COVID-19 vaccines may offer this by generating mucosal immunity. In this open-label, randomised, multicentre, phase 3 clinical trial (CTRI\/2022\/02\/40065; ClinicalTrials.gov: NCT05522335), healthy adults were randomised to receive two doses, 28 days apart, of either intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154) or licensed intramuscular vaccine, Covaxin\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . Between April 16 and June 4, 2022, we enrolled 3160 subjects of whom, 2971 received 2 doses of BBV154 and 161 received Covaxin. On Day 42, 14 days after the second dose, BBV154 induced significant serum neutralization antibody titers against the ancestral (Wuhan) virus, which met the pre-defined superiority criterion for BBV154 over Covaxin\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . Further, both vaccines showed cross protection against Omicron BA.5 variant. Salivary IgA titers were found to be higher in BBV154. In addition, extensive evaluation of T cell immunity revealed comparable responses in both cohorts due to prior infection. However, BBV154 showed significantly more ancestral specific IgA-secreting plasmablasts, post vaccination, whereas Covaxin recipients showed significant Omicron specific IgA-secreting plasmablasts only at day 42. Both vaccines were well tolerated. Overall reported solicited reactions were 6.9% and 25.5% and unsolicited reactions were 1.2% and 3.1% in BBV154 and Covaxin\n                    <jats:sup>\u00ae<\/jats:sup>\n                    participants respectively.\n                  <\/jats:p>","DOI":"10.1038\/s41541-023-00717-8","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:48:57Z","timestamp":1692362937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae)"],"prefix":"10.1038","volume":"8","author":[{"given":"Chandramani","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-3165","authenticated-orcid":false,"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3802-6014","authenticated-orcid":false,"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar Vivek","family":"Redkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Suresh","family":"Bhate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-3765","authenticated-orcid":false,"given":"Vivek","family":"Gundappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rambabu","family":"Konatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leelabati","family":"Toppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket Chandrakant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Singh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Bawankule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raches","family":"Ella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunda","family":"Ganneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth Reddy","family":"Chiteti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivas","family":"Kataram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Mohan","family":"Vadrevu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2213-2600(21)00005-9","volume":"9","author":"T Kirby","year":"2021","unstructured":"Kirby, T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir. Med. 9, e20\u2013e21 (2021).","journal-title":"Lancet Respir. Med."},{"key":"717_CR2","doi-asserted-by":"publisher","first-page":"o66","DOI":"10.1136\/bmj.o66","volume":"376","author":"L Taylor","year":"2022","unstructured":"Taylor, L. Covid-19: Omicron drives weekly record high in global infections. BMJ 376, o66 (2022).","journal-title":"BMJ"},{"key":"717_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"717_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"717_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94719-y","volume":"11","author":"DA Swan","year":"2021","unstructured":"Swan, D. A. et al. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Sci. Rep. 11, 15531 (2021).","journal-title":"Sci. Rep."},{"key":"717_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","volume":"14","author":"O Gallo","year":"2021","unstructured":"Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L. & Annunziato, F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 14, 305\u2013316 (2021).","journal-title":"Mucosal Immunol."},{"key":"717_CR7","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine 75, 103788 (2022).","journal-title":"EBioMedicine"},{"key":"717_CR8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1001\/jama.2021.19063","volume":"326","author":"M Klompas","year":"2021","unstructured":"Klompas, M. Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination. JAMA 326, 2018\u20132020 (2021).","journal-title":"JAMA"},{"key":"717_CR9","doi-asserted-by":"publisher","first-page":"611337","DOI":"10.3389\/fimmu.2020.611337","volume":"11","author":"MW Russell","year":"2020","unstructured":"Russell, M. W., Moldoveanu, Z., Ogra, P. L. & Mestecky, J. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front. Immunol. 11, 611337 (2020).","journal-title":"Front. Immunol."},{"key":"717_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"717_CR11","doi-asserted-by":"publisher","first-page":"1063679","DOI":"10.3389\/fimmu.2022.1063679","volume":"13","author":"R Sunagar","year":"2022","unstructured":"Sunagar, R., Prasad, S. D., Ella, R. & Vadrevu, K. M. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front. Immunol. 13, 1063679 (2022).","journal-title":"Front. Immunol."},{"key":"717_CR12","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).","journal-title":"Cell Rep."},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan, A. O. et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep. Med. 2, 100230 (2021).","journal-title":"Cell Rep. Med."},{"key":"717_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"717_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"717_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"717_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324, 951\u2013960 (2020).","journal-title":"JAMA"},{"key":"717_CR18","doi-asserted-by":"publisher","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","volume":"85","author":"M Madhavan","year":"2022","unstructured":"Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine 85, 104298 (2022).","journal-title":"EBioMedicine"},{"key":"717_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"JX Li","year":"2022","unstructured":"Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739\u2013748 (2022).","journal-title":"Lancet Respir. Med."},{"key":"717_CR20","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.4161\/hv.25458","volume":"9","author":"A Ainai","year":"2013","unstructured":"Ainai, A. et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum. Vaccin Immunother. 9, 1962\u20131970 (2013).","journal-title":"Hum. Vaccin Immunother."},{"key":"717_CR21","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).","journal-title":"Sci. Transl. Med."},{"key":"717_CR22","doi-asserted-by":"publisher","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).","journal-title":"Sci. Transl. Med."},{"key":"717_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep32973","volume":"6","author":"A Dutta","year":"2016","unstructured":"Dutta, A. et al. Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs. Sci. Rep. 6, 32973 (2016).","journal-title":"Sci. Rep."},{"key":"717_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","volume":"10","author":"F Zhu","year":"2022","unstructured":"Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 10, 749\u2013760 (2022).","journal-title":"Lancet Respir. Med."},{"key":"717_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"SA Mendonca","year":"2021","unstructured":"Mendonca, S. A., Lorincz, R., Boucher, P. & Curiel, D. T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 6, 97 (2021).","journal-title":"NPJ Vaccines"},{"key":"717_CR26","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","volume":"385","author":"FC Zhu","year":"2015","unstructured":"Zhu, F. C. et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385, 2272\u20132279 (2015).","journal-title":"Lancet"},{"key":"717_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","volume":"389","author":"FC Zhu","year":"2017","unstructured":"Zhu, F. C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621\u2013628 (2017).","journal-title":"Lancet"},{"key":"717_CR28","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","volume":"3","author":"MA Croyle","year":"2008","unstructured":"Croyle, M. A. et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3, e3548 (2008).","journal-title":"PLoS ONE"},{"key":"717_CR29","doi-asserted-by":"publisher","first-page":"e28214","DOI":"10.1002\/jmv.28214","volume":"95","author":"MC Arjun","year":"2023","unstructured":"Arjun, M. C. et al. Long COVID following Omicron wave in Eastern India-A retrospective cohort study. J. Med. Virol. 95, e28214 (2023).","journal-title":"J. Med. Virol."},{"key":"717_CR30","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","volume":"398","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 398, 2173\u20132184 (2021).","journal-title":"Lancet"},{"key":"717_CR31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis. 21, 950\u2013961 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"717_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16097-3","volume":"12","author":"KM Vadrevu","year":"2022","unstructured":"Vadrevu, K. M. et al. Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Sci. Rep. 12, 12038 (2022).","journal-title":"Sci. Rep."},{"key":"717_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/ijmr.IJMR_2382_20","volume":"152","author":"GR Deshpande","year":"2020","unstructured":"Deshpande, G. R. et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J. Med. Res. 152, 82\u201387 (2020).","journal-title":"Indian J. Med. Res."},{"key":"717_CR34","doi-asserted-by":"publisher","first-page":"109773","DOI":"10.1016\/j.celrep.2021.109773","volume":"37","author":"M Vono","year":"2021","unstructured":"Vono, M. et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep. 37, 109773 (2021).","journal-title":"Cell Rep."},{"key":"717_CR35","doi-asserted-by":"publisher","first-page":"e00827","DOI":"10.1128\/mSphere.00827-20","volume":"5","author":"P Vetter","year":"2020","unstructured":"Vetter, P. et al. Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: a Case Series. mSphere 5, e00827\u201320 (2020).","journal-title":"mSphere"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00717-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:03:29Z","timestamp":1700273009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00717-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00717-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The principal investigators were C.S., S.V., P.R., C.P., M.K.J., S.V.R., A.S.B., V.G., R.K., L.T., A.C.J., J.S.K., A.P.S. and S.B. B.G., S. Re., K.S., R.E., S. Pr, and K.M.V. are employees of Bharat Biotech, with no stock options or incentives. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. M.S.D. and Washington University School of Medicine developed the SARS-CoV-2 ChAd vaccine that was licensed to Bharat Biotech for commercial development, and as such could receive royalty payments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}